Showing results (231-240 of 335) with videos related to
Sort By:
Pageof 34
Cancer|January 20, 2011
Patient willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trialsRaoul Tibes, Barbara F Piper, Jessica A Smith, et al.Journal of Pharmaceutical Sciences|January 8, 2011
Validation of 96-well equilibrium dialysis with non-radiolabeled drug for definitive measurement of protein binding and application to clinical development of highly-bound drugsMaciej J Zamek-Gliszczynski, Kenneth J Ruterbories, Rose T Ajamie, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 13, 2008
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741Hanna K Sanoff, Daniel J Sargent, Megan E Campbell, et al.British Journal of Cancer|June 6, 2014
Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myelomaA Patnaik, G J Weiss, K P Papadopoulos, et al.Journal of Diabetes|October 21, 2014
Pharmacological characterization of ZYDPLA1, a novel long-acting dipeptidyl peptidase-4 inhibitorMukul R Jain, Amit A Joharapurkar, Rajesh H Bahekar, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumorsRamesh K Ramanathan, D Lynn Kirkpatrick, Chandra P Belani, et al.Cancer Therapy|January 9, 2009
A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumorsAndrew J Lepisto, Arthur J Moser, Herbert Zeh, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2008
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE StudyHoward S Hochster, Lowell L Hart, Ramesh K Ramanathan, et al.European Journal of Cancer (Oxford, England : 1990)|September 29, 2014
Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumoursJeffrey R Infante, Glen J Weiss, Suzanne Jones, et al.Investigational New Drugs|July 21, 2017
Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumorsGlen J Weiss, Gayle Jameson, Daniel D Von Hoff, et al.Pageof 34